Iterum Therapeutics Plc Stock Market Value
| ITRM Stock | USD 2.03 0.02 0.98% |
| Symbol | Iterum |
Iterum Therapeutics PLC Price To Book Ratio
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (5.56) |
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Iterum Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Iterum Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Iterum Therapeutics.
| 10/30/2024 |
| 11/29/2024 |
If you would invest 0.00 in Iterum Therapeutics on October 30, 2024 and sell it all today you would earn a total of 0.00 from holding Iterum Therapeutics PLC or generate 0.0% return on investment in Iterum Therapeutics over 30 days. Iterum Therapeutics is related to or competes with Adial Pharmaceuticals, Tonix Pharmaceuticals, Fortress Biotech, Citius Pharmaceuticals, Jaguar Animal, Ibio, and Dermata Therapeutics. Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infecti... More
Iterum Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Iterum Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Iterum Therapeutics PLC upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.93 | |||
| Information Ratio | 0.122 | |||
| Maximum Drawdown | 84.62 | |||
| Value At Risk | (6.19) | |||
| Potential Upside | 8.6 |
Iterum Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Iterum Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Iterum Therapeutics' standard deviation. In reality, there are many statistical measures that can use Iterum Therapeutics historical prices to predict the future Iterum Therapeutics' volatility.| Risk Adjusted Performance | 0.1127 | |||
| Jensen Alpha | 1.43 | |||
| Total Risk Alpha | (0.16) | |||
| Sortino Ratio | 0.1675 | |||
| Treynor Ratio | (0.96) |
Iterum Therapeutics PLC Backtested Returns
Iterum Therapeutics is abnormally volatile given 3 months investment horizon. Iterum Therapeutics PLC holds Efficiency (Sharpe) Ratio of 0.14, which attests that the entity had a 0.14% return per unit of risk over the last 3 months. We were able to interpolate data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.33% are justified by taking the suggested risk. Use Iterum Therapeutics PLC Risk Adjusted Performance of 0.1127, market risk adjusted performance of (0.95), and Downside Deviation of 6.93 to evaluate company specific risk that cannot be diversified away. Iterum Therapeutics holds a performance score of 10 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -1.33, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Iterum Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Iterum Therapeutics is expected to outperform it. Use Iterum Therapeutics PLC value at risk, and the relationship between the jensen alpha and skewness , to analyze future returns on Iterum Therapeutics PLC.
Auto-correlation | 0.80 |
Very good predictability
Iterum Therapeutics PLC has very good predictability. Overlapping area represents the amount of predictability between Iterum Therapeutics time series from 30th of October 2024 to 14th of November 2024 and 14th of November 2024 to 29th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Iterum Therapeutics PLC price movement. The serial correlation of 0.8 indicates that around 80.0% of current Iterum Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.8 | |
| Spearman Rank Test | 0.86 | |
| Residual Average | 0.0 | |
| Price Variance | 0.07 |
Iterum Therapeutics PLC lagged returns against current returns
Autocorrelation, which is Iterum Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Iterum Therapeutics' stock expected returns. We can calculate the autocorrelation of Iterum Therapeutics returns to help us make a trade decision. For example, suppose you find that Iterum Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Iterum Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Iterum Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Iterum Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Iterum Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Iterum Therapeutics Lagged Returns
When evaluating Iterum Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Iterum Therapeutics stock have on its future price. Iterum Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Iterum Therapeutics autocorrelation shows the relationship between Iterum Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Iterum Therapeutics PLC.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Iterum Therapeutics Correlation, Iterum Therapeutics Volatility and Iterum Therapeutics Alpha and Beta module to complement your research on Iterum Therapeutics. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Iterum Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.